The evolution of evaluation of risk for clinically significant prostate cancer

Whatever one may happen to think about the value of the PSA test, we all know that it is very bad at actually telling a doctor or a patient if that patient is at real risk for clinically significant prostate cancer. So, from that perspective … READ MORE …

PSA density vs. PSA level and the prediction of prostate cancer risk

A newly published study in the journal Urology (the “Gold Journal”) has suggested that — at least for patients with a PSA level between 4 and 10 ng/ml — PSA density may be better than PSA level in the determination of which of these patients need to go on to have a biopsy. … READ MORE …

New draft USPSTF guidance on screening for risk of prostate cancer (the details)

As indicated earlier this morning, the US Preventive Services Task Force (USPSTF) has issued new draft guidance on screening for risk of prostate cancer. Access to all the relevant details is provided below: … READ MORE …

USPSTF changes guidance on testing for risk of prostate cancer

As yet we have not seen the details, but, according to a report on National Public Radio early this morning, the US Preventive Services Task Force (USPSTF) has stated that men up to age 70 should discuss the risk and benefits of PSA testing with their doctors and then make individual decisions about whether to get tested. … READ MORE …

MRI as a means of screening for prostate cancer? Probably not!

A report on the HealthDay web site related to a presentation about the role of MRI scanning in the diagnosis of localized prostate cancer seems to demonstrate a significant division of views about the value of standardized use of mpMRI in the diagnosis of prostate cancer. … READ MORE …

Family history, PSA testing, and risk for diagnosis with prostate cancer

A presentation at the ongoing annual meeting of the European Association of Urology (EAU), in London, England, has reported (perhaps unsurprisingly) that PSA testing for risk of prostate cancer based on family history alone is not a very good idea. … READ MORE …

Genetics, PSA, and steps toward a better prostate cancer risk management strategy

A new analysis of a large data set compiled by Kaiser Permanente suggests that combining PSA data with genetic risk data may offer a much more effective way to assess risk for clinically significant prostate cancer. … READ MORE …